Similar Improvements Seen in Secondary Efficacy Measures for FP and SAL vs. PLA

SFCA3007 SFCA3007 SFCA3006 SFCA3006

Measure SAL50 FP250 SAL50 FP500

TDI (dyspnea) ? — —

CRDQ (QOL) — — —

CBSQ (cough/sputum) — — —

PEF ? ? ? ?

NT awakenings — ? ? ?

Ventolin use ? — ? ?

Time to COPD exac. — — — —

= statistically significantly different than placebo

• = P=0.05, FP vs. Placebo

— = Pɬ.05, FP vs. Placebo

*

*

*

*

Previous slide

Next slide

Back to first slide

View graphic version